HomeProductsBioactive CompoundsEndocrine & Hormonal TargetsAndrogen ReceptorApalutamide
Chemical structure of CAS 956104-40-8

Apalutamide

CAS No.956104-40-8
MDL No.MFCD22380626
MFC21H15F4N5O2S
MW477.40
InChI KeyHJBWBFZLDZWPHF-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.956104-40-8
Product NameApalutamide

Biological Targets

AR

Associated Conditions

prostate cancer·prostate carcinoma·prostate adenocarcinoma·neoplasm·cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine • Vol. 378, Issue 15 • 2018
PMID: 29420164DOI: 10.1056/NEJMoa1715546

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

European urology • Vol. 70, Issue 6 • 2016
PMID: 27160947PMC: PMC5568792DOI: 10.1016/j.eururo.2016.04.023

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Scientific reports • Vol. 5 • 2015
PMID: 26137992PMC: PMC4490394DOI: 10.1038/srep12007

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 31, Issue 28 • 2013
PMID: 24002508PMC: PMC3782148DOI: 10.1200/JCO.2013.50.1684

Documentation

Similar Products